Cyclo Therapeutics Inc. (NASDAQ: CYTH)
$1.23
+0.0250 ( +2.08% ) 49.7K
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Market Data
Open
$1.23
Previous close
$1.20
Volume
49.7K
Market cap
$34.91M
Day range
$1.20 - $1.26
52 week range
$0.89 - $2.12
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 05, 2024 |
4 | Insider transactions | 1 | Jun 05, 2024 |
4 | Insider transactions | 1 | Jun 05, 2024 |
10-q | Quarterly Reports | 54 | May 15, 2024 |
10-k/a | Quarterly Reports | 16 | Apr 29, 2024 |
10-k | Annual reports | 119 | Mar 18, 2024 |
8-k/a | 8K-related | 15 | Mar 04, 2024 |
4 | Insider transactions | 1 | Feb 15, 2024 |
4 | Insider transactions | 1 | Feb 15, 2024 |
4 | Insider transactions | 1 | Feb 15, 2024 |